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Abstract
Androgen deprivation therapy (ADT) has been used in the treatment of metastatic prostate cancer since the first
description of its hormonal dependence in 1941. In 2004, docetaxel chemotherapy became the mainstay of treatment
in metastatic castration-resistant prostate cancer (mCRPC), following robust, albeit modest, survival benefit in two
randomized phase 3 trials. The recently published CHAARTED trial was the first to show that combining ADT with
docetaxel in men with hormone-naïve (hormone-sensitive) metastatic prostate cancer (mHSPC) yielded a remarkable
overall survival benefit of 13.6 months as compared with ADT alone. In the current issue of The Lancet, James et al. report
results of the STAMPEDE trial in men with high-risk locally advanced or metastatic prostate cancer initiating long-term
hormone therapy. The combination of six cycles of docetaxel with ADT in men commencing long-term ADT
demonstrated a similar OS benefit compared with standard of care (SOC) by a median of 10 months. Based on
the consistency of the data and the firmness of the benefit provided, docetaxel in addition to ADT should be
considered SOC for men with newly diagnosed mHSPC.
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Background
Docetaxel in metastatic castration-resistant prostate cancer
(mCRPC)
Docetaxel has been available for more than 10 years for
the treatment of metastatic castration resistant prostate
cancer (mCRPC) [1, 2]. The overall survival (OS) benefit
obtained in the pivotal study TAX 327, comparing doce-
taxel plus prednisone and mitoxantrone plus prednisone,
was 2.9 months in the final analysis [3]. Since this sur-
vival benefit was obtained despite confounding effects by
cross-over to docetaxel in a third of patients failing
mitoxantrone, and the benefit in terms of symptom and
quality of life improvements during docetaxel treatment
is frequently obvious, its use was rapidly adopted. With
the advent of the orally-administered novel androgen re-
ceptor (AR) targeted agents, abiraterone and enzalutamide,
docetaxel is increasingly becoming positioned as second-
or even third-line treatment after these AR-targeted treat-
ments. Survival benefit obtained in first-line or second-line
settings, however, may be quite different when used in sub-
sequent lines of treatment. This concern is fueled by in-
creasing evidence from both preclinical and clinical studies
indicating that the efficacy of docetaxel is impaired when
used after novel AR-targeted therapy [4–6]. Using doce-
taxel early in the treatment of prostate cancer, prior to
these agents, might thus provide a new treatment oppor-
tunity in the management of metastatic prostate cancer.
The use of docetaxel in hormone-naïve metastatic prostate
cancer (mHSPC)
Androgen deprivation therapy (ADT) has been used in
the treatment of metastatic prostate cancer since the
first description of its hormonal dependence in 1941 [1].
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Although it is the gold standard treatment for metastatic
prostate cancer, disease progression ultimately becomes
inevitable. The hypothesis that a subpopulation of prostate
cancer cells may be AR-negative, and thus resistant to
ADT from the beginning, was the rationale for combining
ADT with docetaxel in men with hormone-naïve meta-
static prostate cancer (mHSPC). In the CHAARTED study
[7], 790 men with mHSPC were randomized to six cycles
of docetaxel plus ADT versus ADTalone. Men were strati-
fied according to high- or low-volume disease, with high-
volume defined as visceral metastases or ≥4 bone lesions
with ≥1 beyond the vertebral bodies and pelvis. Median
OS was 57.6 months for men treated with docetaxel plus
ADT versus 44 months for ADT alone (13.6 months lon-
ger, hazard ratio (HR), 0.61; 95 % confidence interval (CI),
0.47–0.80; P <0.001). In men with high-volume disease,
the treatment effect of docetaxel plus ADT was even more
pronounced, with an OS benefit of 17 months (49 vs.
32 months; HR, 0.60; 95 % CI, 0.45–0.81; P <0.001). In the
low-volume subgroup, median OS was not yet reached.
STAMPEDE is a multi-arm, multistage trial that in-
cluded both metastatic and non-metastatic prostate can-
cer patients [8]. The current report of the STAMPEDE
trial reflects results of four study arms, including standard
of care (SOC; ADT ± radiotherapy), SOC plus docetaxel,
SOC plus zoledronic acid, and SOC plus docetaxel and
zoledronic acid [8]. Docetaxel was administered as six cy-
cles of 75 mg/m2 every 3 weeks with prednisone 10 mg
daily. Approximately 61 % of patients had metastatic dis-
ease (by TNM criteria) at the time of inclusion in the
study, whereas 15 % presented with node positive disease
and 24 % with high-risk locally advanced disease (T3/4,
PSA >40 or Gleason 8–10). The STAMPEDE study dem-
onstrated that docetaxel in combination with SOC im-
proved OS by 10 months as compared with SOC alone
(HR, 0.78; 95 % CI, 0.66–0.93; P = 0.006). When confined
to patients with metastatic disease, the OS benefit was
15 months for docetaxel plus SOC versus SOC alone (HR,
0.76; 95 % CI, 0.62–0.92; P = 0.005). For patients with
non-metastatic disease, median OS was not yet reached
and statistical significance could not be demonstrated.
Findings in perspective
Two large randomized trials have now shown a robust
and clinically meaningful survival benefit by the addition
of docetaxel to ADT in men with mHSPC [7, 8]. The
magnitude of the OS in the CHAARTED and STAM-
PEDE trials is remarkable (13.6 and 15 months in the
metastatic patient population, respectively) and much
larger than obtained with the use of chemotherapeutic
or novel hormonal agents in the setting of mCRPC. A
meta-analysis of the available data, also incorporating a
smaller study by the French Genitourinary Tumor Group
(GETUG-15) that showed a similar trend but did not reach
statistical significance, is reported by Vale et al. [9] in the
current issue of The Lancet Oncology. The meta-analysis
revealed a robust 9 % absolute OS benefit at 4 years by the
use of docetaxel plus ADT in men with mHSPC [9]. Con-
sequently, these results should be considered as practice
changing in the daily treatment of men with prostate can-
cer. Men with newly diagnosed mHSPC, who are consid-
ered fit to receive chemotherapy, should be offered six
cycles of docetaxel in addition to ADT.
However, some questions remain unsolved. Which pa-
tients precisely benefit from six cycles of docetaxel?
Should docetaxel be administered with or without pred-
nisone? And what is the explanation for the magnitude
of the benefit by applying docetaxel early?
The CHAARTED study stratified for high- versus low-
volume disease and only showed a statistically significant
OS benefit in the high-volume subgroup. For men with
low-volume disease, the number of events was too small
at the time of reporting and therefore longer follow-up
is awaited. The STAMPEDE trial, on the other hand, did
not stratify for volume of metastatic disease and demon-
strated clinical benefit for the entire patient population.
These findings, in by far the largest study, in combination
with the results from the meta-analysis incorporating low-
volume metastatic patients, demonstrate that docetaxel
plus ADT should be considered in all men with mHSPC
regardless of disease burden.
Whereas the benefit of docetaxel is clearly visible in
metastatic patients, longer follow-up will be needed to draw
conclusions for non-metastatic patients. Likewise, since the
vast majority of men included in both STAMPEDE and
CHAARTED studies presented with newly diagnosed meta-
static prostate cancer, conclusions regarding the use of do-
cetaxel in men previously treated for local disease are also
limited. To date, the recommendation of docetaxel plus
ADT thus reflects the setting of newly diagnosed metastatic
disease. For those patients, however, in whom metastatic
disease becomes apparent within months after local treat-
ment and the true extent of disease may have been missed
upfront, treatment decisions should be individualized and
preferably weighed in the multidisciplinary setting of mod-
ern patient care.
The reasons that underlie the greater benefit by using six
cycles of docetaxel in the hormone-naïve setting as com-
pared to the castrate-resistant setting might be sought in
the early kill of hormone-resistant cell clones, as previously
suggested by Sweeney et al. [7]. An alternative or additional
explanation could lie in different docetaxel pharmacokinet-
ics. The incidence of neutropenic fever in TAX 327 was
2.7 %, whereas the incidence in all three mHSPC studies
ranged from 6 to 12 %. These findings may suggest differ-
ent docetaxel exposure in mCRPC as compared with
mHSPC patients. Franke et al. [10] have shown that the
clearance of docetaxel is affected by a castrate status. In
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their study, the clearance of docetaxel was increased by
100 % in castrated as compared to non-castrated men,
resulting in a significantly higher area under the curve.
Steroids are CYP3A4 inducers and may therefore influ-
ence taxane pharmacokinetics. A recent Danish report sug-
gested a higher incidence of neutropenic fever in patients
receiving docetaxel alone as compared to docetaxel with
prednisone [11]. In the CHAARTED trial, docetaxel was
given without prednisone. However, STAMPEDE produced
similar survival benefit as observed in CHAARTED despite
docetaxel being co-administered with prednisone. Although
it is conceivable that prednisone might impact docetaxel
clearance and may reduce docetaxel exposure, the addition
of prednisone clearly enhances the efficacy of the regimen.
To substantiate, the recently reported study on orteronel
plus prednisone versus prednisone alone in chemotherapy-
naïve men with mCRPC showed a 28 % prostate-specific
antigen (PSA) response rate and 25 % circulating tumor cell
conversion rate at 12 weeks in men receiving prednisone
alone [12]. Considering these data, the recommendation is
to co-administer docetaxel with prednisone.
Conclusions
In conclusion, the survival benefit obtained by docetaxel
in men with mHSPC is consistent, and much larger than
when given at the time of mCRPC. Thus, six cycles of
docetaxel plus ADT should be the new standard of care
in men with newly diagnosed metastatic prostate cancer.
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